a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

AstraZeneca’s new inhaler Bevespi Aerosphere (glycopyrronium ... to relieve symptoms in adults with COPD. Bevespi, which is taken twice daily, is part of a new generation of medicines that ...

Tiotropium and aclidinium are currently available for prescription. Tiotropium is a once-daily inhaled ultra-LAMA for COPD that works through prolonged blockade of the M 3 muscarinic receptor.

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Flare-ups in chronic obstructive pulmonary disease, the UK’s fourth leading cause of death, can be reduced by 20% by a combined triple inhaler, according to the results of a trial of more than 2,000 ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There was a ...